Alport syndrome: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Alport syndrome is a rare genetic disorder caused by mutations in COL4A3-5 genes, disrupting type IV collagen production. This leads to progressive glomerular basement membrane damage, resulting in hematuria, proteinuria, and eventual kidney failure. Extrarenal manifestations include sensorineural hearing loss (30–50%) and ocular abnormalities (e.g., anterior lenticonus). X-linked inheritance accounts for 80–85% of cases. Treatment focuses on RAAS blockade (ACE inhibitors/ARBs) to slow kidney disease progression, with dialysis or transplant required for end-stage renal disease [1][2][12].

Population

Prevalence: ~1 in 50,000 live births worldwide [4][16]; affects ~30,000–60,000 individuals in the U.S. [2][19].
Inheritance: X-linked (80–85%), autosomal recessive (15%), or dominant (rare) [12][16].
Severity: Males with X-linked form often develop ESRD by age 40; females typically have milder symptoms [12][16].

Burden

Clinical: ESRD in >90% of untreated X-linked males by mid-adulthood; hearing loss in 30–50%, ocular defects in ~30% [2][12][16].
Economic: Lifetime costs of dialysis/transplant; off-label drug use increases financial strain [3][5].
Psychosocial: Impacts quality of life due to multisystem involvement and hereditary transmission risks [5][18].

Therapies

RAAS inhibitors (ACEi/ARBs): First-line to reduce proteinuria and delay CKD progression [1][6][13].
SGLT2 inhibitors: Emerging adjunct therapy for CKD management [3][13].
Renal replacement: Dialysis or transplantation for ESRD; transplants show high success but require donor screening [1][2][18].

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare otorhinolaryngological diseases, rare renal diseases, rare transplant-related disorders

Research Papers

588 drug discovery papers related to Alport syndrome, with 5 first-in-class and 9 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-05-29 | Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases.

The global burden of chronic and genetic kidney diseases poses a significant challenge to healthcare systems. Current therapies, including dialysis, transplantation, and supportive pharmacotherapies, cannot halt disease progression or address root causes, especially in monogenic disorders like Alport syndrome and Fabry disease. Adeno-associated virus (AAV)-based gene therapy is promising, enabling targeted correction of underlying genetic defects. However, renal delivery faces challenges, including cellular heterogeneity, anatomical barriers, and pre-existing immunity. This review evaluates advances in AAV capsid engineering to overcome these obstacles, focusing on strategies to enhance kidney-specific tropism, transduction efficiency, and immune evasion. We outline the evolution from conventional serotype selection to precision engineering via rational design, directed evolution, and in silico approaches. Artificial intelligence (AI) has emerged as a pivotal accelerator, with machine learning models and generative frameworks enabling data-efficient capsid optimization despite limited datasets. Multimodal AI, reinforcement learning, and agentic systems can refine renal targeting by balancing glomerular penetration, cell specificity, and safety. Future progress relies on scaling high-quality datasets through collaborative consortia, lab-in-the-loop validation, and explainable AI. By combining capsid engineering with renal pathophysiology insights, this roadmap paves the way for curative AAV therapies that move beyond current suboptimal treatments to correct underlying pathogenic mechanisms.

Open article ↗

2026-05-28 | Alport syndrome: a genetically confirmed x-linked case with early family screening.

Alport syndrome (AS) is an inherited disorder of the glomerular basement membrane (GBM) resulting from pathogenic variants in the COL4A3, COL4A4, or COL4A5 genes, which encode the α3, α4, and α5 chains of type IV collagen, the main structural component of the GBM, cochlea, and lens capsule.Defects in this collagen network lead to progressive renal insufficiency, hearing impairment, and characteristic ocular lesions such as anterior lenticonus and retinal flecks.(1).AS affects approximately 1 in 50 000 live births.The disease is classically inherited in an X-linked pattern (85%), followed by autosomal recessive (15%) and autosomal dominant (< 1%) forms.The severity and age at onset vary depending on the mutation type and zygosity, with males with truncating COL4A5 variants typically progressing faster to end-stage kidney disease (ESKD).( 2 )

Open article ↗

2026-05-29 | Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases.

Open article ↗

2026-05-28 | Alport syndrome: a genetically confirmed x-linked case with early family screening.

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

14 orphan drug designations for Alport syndrome.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
Exaluren sulfate	small molecules	EMA	2026-03-25	—	FGK Representative Service GmbH
a human monoclonal antibody that blocks the function of semaphorin-3A	antibodies	FDA	2025-05-07	—	Bayer HealthCare Pharmaceuticals Inc.
6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-alpha-Ltalofuranosyl)-paromamine sulfate	small molecules	FDA	2024-04-10	—	Eloxx Pharmaceuticals Inc.
Setanaxib	small molecules	EMA	2023-11-08	—	Calliditas Therapeutics France S.A.S.
setanaxib	small molecules	FDA	2023-09-26	—	Calliditas Therapeutics AB
Vonafexor	small molecules	FDA	2023-08-09	—	ENYO Pharma
Vonafexor	small molecules	EMA	2023-07-25	—	ENYO Pharma
5-(3,4-Dichloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide	small molecules	EMA	2023-06-20	—	Veristat Spain S.L.
5-Arylnicotinamide ABCA1 inducer	small molecules	FDA	2023-02-22	—	River 3 Renal Corp.
Ivaltinostat	small molecules	FDA	2021-11-04	—	CG Invites Co., Ltd.
Bardoxolone methyl	small molecules	EMA	2018-05-25	—	Reata Ireland Limited
bardoxolone methyl	small molecules	FDA	2017-07-03	—	Reata Pharmaceuticals, Inc.
Lademirsen [RG-012]	oligonucleotides	EMA	2015-03-19	—	Sanofi B.V.
single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21	oligonucleotides	FDA	2014-07-17	—	Genzyme Corporation

Alport syndrome

Alport syndrome

Alport syndrome

Overview

Population

Burden

Therapies

Categories: rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare otorhinolaryngological diseases, rare renal diseases, rare transplant-related disorders

Research Papers

2026-05-29 | Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases.

2026-05-28 | Alport syndrome: a genetically confirmed x-linked case with early family screening.

2026-05-29 | Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases.

2026-05-28 | Alport syndrome: a genetically confirmed x-linked case with early family screening.

Drug Discovery Landscape

Updated: Jul 29, 2026